NCT04328844 2026-03-30
A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers
iOnctura
Phase 1 Active not recruiting
Clinical Trials
14 trialsNCT03357757 2025-06-26
LATENT
AHS Cancer Control Alberta
Phase 2 Completed
NCT03440567 2025-03-26
Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma
City of Hope Medical Center
Phase 1 Completed
NCT03169790 2025-02-24
QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL
ImmunityBio, Inc.
Phase 1/2 Withdrawn
NCT03636503 2025-02-06
Rituximab + Immunotherapy in Follicular Lymphoma
Dana-Farber Cancer Institute
Phase 1 Terminated
NCT03244176 2024-07-30
AvR-CHOP
Austin Health
Phase EARLY_PHASE1 Active not recruiting
NCT03046953 2024-07-16
AVAIL-T
University of Birmingham
Phase 2 Completed
NCT03451825 2024-06-24
Phase I/II Study of Avelumab in Pediatric Cancer Participants
EMD Serono
Phase 1 Terminated
NCT03617666 2023-12-12
AVENuE
University College, London
Phase 2 Unknown
NCT03905135 2022-09-13
Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT03439501 2021-09-24
Avelumab in Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma[AVENT STUDY]
Samsung Medical Center
Phase 2 Unknown
NCT02951156 2020-12-17
Javelin DLBCL
Pfizer
Phase 3 Terminated
NCT02603419 2020-04-24
JAVELIN HODGKINS
Pfizer
Phase 1 Terminated
NCT03147404 2019-12-30
MS100070-0177
Samsung Medical Center
Phase 2 Completed